Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
June 16, 2024 05:30 ET
|
Nurix Therapeutics, Inc.
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and...
NASP Petitions SCOTUS to Reverse Lower Court Decision on Oklahoma Law and to Protect Specialty Pharmacies
June 15, 2024 09:21 ET
|
National Association of Specialty Pharmacy (NASP)
Washington, DC, June 15, 2024 (GLOBE NEWSWIRE) -- The National Association of Specialty Pharmacy (NASP) has filed a petition before the U.S. Supreme Court, asking that the Court agree to support the...
Global surge in infectious diseases as over 40 countries report outbreaks 10-fold over pre-pandemic levels
June 14, 2024 14:00 ET
|
Airfinity
London, England, June 14, 2024 (GLOBE NEWSWIRE) -- Global surge in infectious diseases as over 40 countries report outbreaks 10-fold over pre-pandemic levels New analysis by Airfinity and...
New Fisher House Under Construction at the Little Rock VA
June 14, 2024 13:46 ET
|
Fisher House Foundation
Little Rock, Arkansas, June 14, 2024 (GLOBE NEWSWIRE) -- Ground was broken today for a Fisher House supporting the Central Arkansas Veterans Healthcare System in Little Rock, Arkansas. It will be...
Chiesi Global Rare Diseases Showcases Ongoing Commitment to Multiple Rare Diseases Communities at ENDO 2024 Meeting Debut
June 14, 2024 11:57 ET
|
Chiesi Global Rare Diseases
• Results presented from a large, pooled database from three Phase 3 clinical trials evaluating MYCAPSSA (octreotide) for the treatment of people living with acromegaly • Additional presentations...
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
June 14, 2024 08:45 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
Tumor Ablation Market Set to Reach $1.4B by 2029 Boasting 10.0% CAGR | MarketsandMarkets™
June 14, 2024 08:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, June 14, 2024 (GLOBE NEWSWIRE) -- Discover the lucrative potential of the global tumor ablation market projected to soar from $0.8 billion in 2024 to an impressive $1.4 billion by 2029,...
ElmediX Plans Series A Round Based on Strong Signals in a Clinical Study for Pancreatic Cancer Patients at the University Hospital Antwerp (Belgium)
June 14, 2024 08:03 ET
|
Elmedix
A novel and innovative approach to treating metastasized cancer, starting with the very lethal grade 4 pancreatic cancer. Earlier this year, scientists from Columbia University in New...
Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors
June 14, 2024 08:00 ET
|
Mineralys Therapeutics, Inc.
RADNOR, Pa., June 14, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic...
Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress
June 14, 2024 07:30 ET
|
Disc Medicine Inc
Updated analyses of data from AURORA and BEACON studies further demonstrate clinical activity of bitopertin across multiple measures of erythropoietic protoporphyria (EPP) and support development path...